NCT01522976 2026-03-18
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
18 trialsNCT03269669 2026-03-18
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06169215 2026-03-18
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01351896 2025-11-20
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01553149 2025-01-07
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02728102 2024-05-07
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT00352365 2022-02-11
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00553644 2018-10-30
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00942578 2018-10-11
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01675141 2018-02-05
Lenalidomide Maintenance Therapy for Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00410605 2017-09-01
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00482911 2017-03-27
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00109005 2017-01-02
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01271283 2015-06-04
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00227591 2014-05-21
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00439231 2014-01-13
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown